Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-T

Stopped early

Conditions studied: HIV-1-infection

In brief

Long-term follow-up of HIV-infected subjects who received SB-728-T or SB-728mR-T. Enrolling subjects will be followed for a total of 12 years.

Key facts

Study ID

NCT04201782

Run by

Sangamo Therapeutics

People needed

38

Starts

2011-03-18

Expected to finish

2023-07-17

Last updated by the study team

2024-01-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects who have, in previous Sangamo clinical trial received SB-728-T or SB-728mR-T, autologous T-cells genetically modified at the CCR5 gene by zinc finger nucleases and give consent to participate in the long-term follow-up study.

You may not qualify if…

• There are no exclusion criteria for this study.

Where it is running

• Quest Clinical Research — San Francisco, California, United States
• Circle CARE Center, LLC — Norwalk, Connecticut, United States
• Orlando Immunology Center — Orlando, Florida, United States
• Central Texas Clinical Research — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.